natera | Prospera™ Transplant assessment

Explore a new technology for more-informed rejection assessment

Join us in understanding how the quantification of background cell-free DNA (cfDNA) may facilitate more precise rejection assessment and flag patients at high risk for false-negative interpretations.



The PEDAL Study for Kidney Transplant Patients

Prospera **E**nhancement by **D**etecting Background Cell-free DNA **L**evels

PEDAL Study

Together with our study collaborators, we hope to gain a better understanding of how quantifying the absolute concentration of background cell-free DNA (cfDNA) may allow for a more precise and confident assessment of allograft rejection—especially in identifying patients at-risk of false-negative interpretations.

Defining background cell-free DNA and its influence on your result



Let's understand how to more precisely assess for active rejection

Prospera™ and the PEDAL Study will delve deeper into how to better manage your transplant patients using cfDNA as a non-invasive biomarker for active rejection. The study will include 500 kidney transplant patients from 20 major U.S. centers to measure diagnostic capability of the update across three critical measures:

1. **Performance in both clinically indicated and surveillance biopsies**
2. **Ability to identify both antibody mediated rejection and T cell-mediated rejection**
3. **Correlation against clinical and/or histological resolution of rejection**

Prospera's core technology

Leveraging our findings from two million cfDNA tests, Prospera is designed to assess kidney transplant injury by evaluating the percentage of donor-derived cell-free DNA (dd-cfDNA) in a transplant recipient's blood. Too much dd-cfDNA in the recipient's blood is an early indication of potential organ rejection.



Based on our leadership in cfDNA innovation, Natera has now introduced two novel techniques for even greater precision in Prospera results:

Two novel techniques for greater precision

1.

Proprietary Library Preparation

Proprietary library preparation step that adjusts for background cfDNA introduced into the sample during transport

+

2.

Quantifed Background CfDNA

Unique quantification method that can identify atypical background cfDNA that may influence the reported result for a particular patient



=

Potentially fewer false negative interpretations

PEDAL STUDY ELIGIBILITY

Inclusion Criteria	Exclusion Criteria
Must be willing to provide informed consent	Cannot have other non-kidney transplanted organ(s)
Must be a kidney transplant recipient	Cannot be pregnant
	Cannot have genetically identical donor organs

We need your help to enable patients to thrive and prosper

With Prospera, we delivered a non-invasive way to identify rejection, giving you greater confidence in making treatment decisions for your organ transplantation patients. But we can do more—we're committed to continue refining this test to support you in bringing hope to these patients. Starting now.

Through PEDAL and other studies, we look to you as our partner in delivering innovations that offer a second chance to patients. Because together, we can make meaningful changes—in individual lives and the field of organ transplantation.

1 Organ Donation Statistics. U.S. Department of Health and Human Services. U.S. Government Information on Organ Donation and Transplantation. https://www.organdonor.gov/statistics-stories/statistics.html. Published March 31, 2016.
2 Kidney Disease Statistics for the United States. National Institute of Diabetes and Digestive and Kidney Diseases. https://www.niddk.nih.gov/health-information/health-statistics/kidney-disease. Published Dec. 1, 2016.
3 Stegall et al,Through a Glass Darkly: Seeking Clarity in Preventing Late Kidney Transplant Failure, *J Am Soc Nephrol*. 2015; 26 (1):20-9
4 Lamb et al, Long-term renal allograft survival in the United States: a critical reappraisal, *Am J of Transplantation*. 2011; Mar;11(3):450-62.5. Altug, et al.
5 Sigdel TK, et al. *J. Clin. Med*. 2019, 8, 19.

For more information, visit:
natera.com/prospera
pedal@natera.com

natera®
Conceive. Deliver. Thrive.

The PEDAL Study for Kidney Transplant Patients

Prospera **E**nhancement by **D**etecting Background cfDNA **L**evels

A kidney transplant is the greatest gift that can be given or received. Such a precious treasure must be cared for with the utmost diligence and attention.

A precise, non-invasive biomarker for rejection gives you the confidence you need to know that all is well. Natera will continue to refine and improve Prospera now and in the future. **We understand the importance of caring for patients and will always be your best partner.**

natera® | **Prospera™**
Transplant assessment

The PEDAL Study
A Study For
KIDNEY TRANSPLANT PATIENTS

natera.com/prospera
pedal@natera.com